Literature DB >> 22786447

Thyroid function influences serum apolipoprotein B-48 levels in patients with thyroid disease.

Satomi Mugii1, Hiroyuki Hanada, Manabu Okubo, Daisaku Masuda, Keiko Takeoka, Yoh Hidaka, Tohru Ohama, Akifumi Matsuyama, Yumiko Nakagawa-Toyama, Makoto Nishida, Masato Ishigami, Issei Komuro, Shizuya Yamashita.   

Abstract

AIM: Apolipoprotein B-48 (apoB-48) is a major apolipoprotein of intestine-derived chylomicrons (CM) and CM remnants (CMR). Clinically overt hypothyroidism (OH) has been associated with premature and accelerated coronary atherosclerosis. To clarify the clinical significance of apoB-48 measurement in patients with thyroid disease, we investigated the correlations between the serum apoB-48 level and thyroid hormones.
METHODS: From outpatients of Osaka University Hospital, patients with OH, subjects with subclinical hypothyroidism (SH) and subjects with normal thyroid function were collected and analyzed by measuring serum TSH, FT4 and FT3 levels. Serum apoB-48 levels were measured by a chemiluminescence enzyme immunoassay and the correlations with thyroid hormone levels or lipid profiles were assessed. These levels were compared among subjects with OH, SH and healthy controls.
RESULTS: Serum apoB-48 level was correlated with TSH, total cholesterol (TC) and triglycerides (TG), but negatively with FT4 and FT3 level. LDL-C and HDL-C levels were not correlated with serum apoB-48 levels. Serum apoB-48 in patients with OH (7.4 ± 5.9 µg/mL) was significantly higher than in those with hyperthyroidism (5.1 ± 3.5 µg/mL; p<0.01) and normal subjects (4.7 ± 3.7 µg/mL; p<0.01), but decreased after levo-thyroxine replacement. ApoB-48, TG and TSH were significantly higher in SH subjects than normal subjects, suggesting that serum apoB-48 level depends on the thyroid function status, similar to TC, LDL-C and TG.
CONCLUSION: Increased serum apoB-48 concentrations and CMR may contribute to the increased risk of atherosclerosis and premature coronary artery disease in the hypothyroid state.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22786447     DOI: 10.5551/jat.12757

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  2 in total

Review 1.  Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism.

Authors:  Huixing Liu; Daoquan Peng
Journal:  Endocr Connect       Date:  2022-02-07       Impact factor: 3.335

Review 2.  Novel insights into the pathological development of dyslipidemia in patients with hypothyroidism.

Authors:  Xin Su; Xiang Chen; Hua Peng; Jingjin Song; Bin Wang; Xijie Wu
Journal:  Bosn J Basic Med Sci       Date:  2022-06-01       Impact factor: 3.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.